Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Fama–French Factor Graphs is a Python-based analytical tool for visualising factor model regressions using the Fama–French framework. The program enables users to plot and compare exposures to the ...

Abstract: This paper proposes a novel matrix-factorization-based recursive filtering algorithm for state estimation in discrete nonlinear complex networks operating under low duty cycle scheduling ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Are you ahead, or behind on retirement? SmartAsset's free ...

As of March 31, Recursion Pharmaceuticals had a cash position of $509 million. Following Tuesday’s layoffs, the biotech expects its runway to last into the fourth quarter of 2027. Recursion ...

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported ...

^^^^^ File "/home/admin/.venv/lib/python3.12/site-packages/opentelemetry/instrumentation/urllib3/__init__.py", line 316, in instrumented_urlopen return wrapped(*args ...